Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
Leukemia & Lymphoma
|
July 9, 2019
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years
Qaiser Bashir, Kamal Chamoun, Denái R Milton, et al.
Future Oncology (London, England)
|
April 23, 2024
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Paula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
The New England Journal of Medicine
|
February 10, 2023
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 7, 2016
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results
Partow Kebriaei, Roland Bassett, Genevieve Lyons, et al.
British Journal of Haematology
|
March 16, 2017
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
Nina Shah, Li Li, Jessica McCarty, et al.
Transplantation and Cellular Therapy
|
September 27, 2023
Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma
Ethan P Damron, Muzaffar H Qazilbash, Penny Q Fang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 18, 2016
Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation
Fabian Bock, Gary Lu, Samer A Srour, et al.
Blood Advances
|
January 9, 2025
Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study
Othman Salim Akhtar, Temitope Oloyede, Ruta Brazauskas, et al.
Transplantation and Cellular Therapy
|
September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium
Karen Sweiss, Charlotte Wagner, Eric Anto, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 23, 2016
Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review
Chelsea C Pinnix, Jatin J Shah, Hubert Chuang, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
Leukemia & Lymphoma
|
July 9, 2019
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years
Qaiser Bashir, Kamal Chamoun, Denái R Milton, et al.
Future Oncology (London, England)
|
April 23, 2024
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Paula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
The New England Journal of Medicine
|
February 10, 2023
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 7, 2016
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results
Partow Kebriaei, Roland Bassett, Genevieve Lyons, et al.
British Journal of Haematology
|
March 16, 2017
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
Nina Shah, Li Li, Jessica McCarty, et al.
Transplantation and Cellular Therapy
|
September 27, 2023
Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma
Ethan P Damron, Muzaffar H Qazilbash, Penny Q Fang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 18, 2016
Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation
Fabian Bock, Gary Lu, Samer A Srour, et al.
Blood Advances
|
January 9, 2025
Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study
Othman Salim Akhtar, Temitope Oloyede, Ruta Brazauskas, et al.
Transplantation and Cellular Therapy
|
September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium
Karen Sweiss, Charlotte Wagner, Eric Anto, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 23, 2016
Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review
Chelsea C Pinnix, Jatin J Shah, Hubert Chuang, et al.
Page
of 8